T. N. Trushnikova

  • Citations Per Year
Learn More
For a study of the serotonergic mechanisms of a fatigue syndrome, we examined 60 patients with remitting and secondary progressive multiple sclerosis and 12 healthy persons. The serotonin content in the platelets of the peripheral blood was measured using an immunoenzymatic assay. Signs of the fatigue syndrome were evaluated according to the FSS scale. In(More)
The expression of semaphorin CD100 by intact peripheral blood T lymphocytes from patients with multiple sclerosis (MS) not receiving immunomodulatory treatment was studied. Cellular CD100 expression levels were assessed, along with levels of CD72 receptor-carrying B lymphocytes. Significant differences were seen between the levels of CD100 expression in(More)
Objective. To study serum concentrations of BDNF and CNTF in patients with multiple sclerosis (MS) and compare them to clinical characteristics of MS. Material and methods. We examined 43 patients with confirmed diagnosis of MS according to McDonald's criteria with remitting type of disease course. Patients were in a stable condition and did not receive(More)
Sixty patients with multiple sclerosis and 12 healthy controls were examined. The fatigue was measured by the Fatigue Severity Scale (FSS). Concentration of platelet serotonin was analyzed with immunoassay techniques («Serotonin ELISA"). The results of the study have shown the primary role of fatigue in multiple sclerosis, with the prevalence of this(More)
The expression of CD100 semaphorin by the intact peripheral blood T lymphocytes in multiple sclerosis (MS) has been studied. The level of middle florescence intensity (MFI) and the number of B-lymphocytes bearing CD72 were evaluated. There were significant differences in the level of CD100 in patients compared to healthy volunteers. These data suggest the(More)
Disease-modifying drugs (DMD) are currently used in the treatment of patients with multiple sclerosis (MS) in accordance with therapeutic standards, with the aim of decreasing the risk of developing exacerbations and thus reducing the rate of development of disability. However, the use of first-line substances is not successful in all cases. Second-line(More)
  • 1